Search | Clinical Trials Finder

Conditions: Pulmonary Hypertension Associated With Interstitial Lung Disease
Interventions: Placebo, Seralutinib, Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: GB002, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Fresno, California • Albuquerque, New Mexico • Richmond, Virginia

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: INOpulse®, Placebo, Open Label Extension; Combination Product
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 61
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 49 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 18
States / cities: Phoenix, Arizona • Fresno, California • Los Angeles, California + 14 more

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Ambrisentan, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 51
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Davis, California + 40 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Dry Powder Inhaler, Placebo; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 20 more

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 79 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 4 more

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Iloprost Inhalation Solution (Ventavis); Drug
Lead sponsor: Actelion; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Treprostinil Palmitil Inhalation Powder, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Naples, Florida • Bend, Oregon

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Lung Diseases
Interventions: L606 inhalation suspension; Combination Product
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more

Conditions: Sarcoidosis, Pulmonary Arterial Hypertension
Interventions: Iloprost; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions: Placebo, LAM-001; Drug
Lead sponsor: IRulya Therapeutics Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 32
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 24 more

Conditions: Idiopathic Interstitial Pneumonias / Hypertension,Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 17
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 14 more

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Sarcoidosis, Respiratory Bronchiolitis Associated Interstitial Lung Disease, Desquamative Interstitial Pneumonia, Cryptogenic Organizing Pneumonia, Acute Interstitial Pneumonitis, Idiopathic Lymphoid Interstitial Pneumonia, Idiopathic Pleuroparenchymal Fibroelastosis
Interventions: Bardoxolone methyl, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 30
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 20 more

Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Interventions: Prospective study assessments; Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 70
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more

Conditions: Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions: ROC-101; Drug
Lead sponsor: AllRock Bio, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 11
States / cities: Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: INOpulse®, Placebo, Long Term Follow Up; Combination Product
Lead sponsor: Bellerophon; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 23
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more

Conditions: Pulmonary Hypertension
Interventions: NX1011; Drug
Lead sponsor: NITROX, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 6
States / cities: Phoenix, Arizona • La Jolla, California • Newark, Delaware + 3 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: inhaled mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more

Conditions: Interstitial Lung Disease, Scleroderma, Pulmonary Hypertension
Interventions: Opsumit 10 Mg Tablet; Drug
Lead sponsor: Franz Rischard, DO; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Pulmonary Hypertension Due to Lung Disease (Disorder)
Interventions: L606, Placebo; Drug
Lead sponsor: Liquidia Technologies, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 12
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 9 more

Conditions: Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions: iNO; Combination Product
Lead sponsor: Bellerophon; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Treprostinil sodium for inhalation; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 6
States / cities: La Jolla, California • Sacramento, California • Ann Arbor, Michigan + 3 more

Conditions: Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: Mosliciguat, Placebo, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Kissimmee, Florida • Louisville, Kentucky • Bend, Oregon

Search by objective public record fields.

Efficacy and Safety of Seralutinib in Adult Subjects With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension

Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

A Study of Mosliciguat in PH-ILD

Oral Treprostinil in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Efficacy and Safety of Riociguat in Patients With Symptomatic Pulmonary Hypertension (PH) Associated With Idiopathic Interstitial Pneumonias (IIP)

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Hypertension Associated With Pulmonary Fibrosis

Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated ILD and PH

A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

PatientSpot Formerly Known as ArthritisPower

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)